These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 14871958)

  • 1. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.
    Vonderheide RH; Domchek SM; Schultze JL; George DJ; Hoar KM; Chen DY; Stephans KF; Masutomi K; Loda M; Xia Z; Anderson KS; Hahn WC; Nadler LM
    Clin Cancer Res; 2004 Feb; 10(3):828-39. PubMed ID: 14871958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).
    Liao ZL; Tang XD; Lü MH; Wu YY; Cao YL; Fang DC; Yang SM; Guo H
    Cancer Sci; 2012 Nov; 103(11):1920-8. PubMed ID: 22909416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
    Parkhurst MR; Riley JP; Igarashi T; Li Y; Robbins PF; Rosenberg SA
    Clin Cancer Res; 2004 Jul; 10(14):4688-98. PubMed ID: 15269141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.
    Adotévi O; Mollier K; Neuveut C; Dosset M; Ravel P; Fridman WH; Tartour E; Charneau P; Wain-Hobson S; Langlade-Demoyen P
    Blood; 2010 Apr; 115(15):3025-32. PubMed ID: 20130242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
    Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
    Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes.
    Schroers R; Shen L; Rollins L; Rooney CM; Slawin K; Sonderstrup G; Huang XF; Chen SY
    Clin Cancer Res; 2003 Oct; 9(13):4743-55. PubMed ID: 14581345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
    Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
    Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.
    Aloysius MM; Mc Kechnie AJ; Robins RA; Verma C; Eremin JM; Farzaneh F; Habib NA; Bhalla J; Hardwick NR; Satthaporn S; Sreenivasan T; El-Sheemy M; Eremin O
    J Transl Med; 2009 Mar; 7():18. PubMed ID: 19298672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.
    Su Z; Dannull J; Yang BK; Dahm P; Coleman D; Yancey D; Sichi S; Niedzwiecki D; Boczkowski D; Gilboa E; Vieweg J
    J Immunol; 2005 Mar; 174(6):3798-807. PubMed ID: 15749921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT.
    Chen DY; Vance BA; Thompson LB; Domchek SM; Vonderheide RH
    Cancer Biol Ther; 2007 Dec; 6(12):1991-6. PubMed ID: 18087213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro.
    Liao ZL; Luo G; Xie X; Tang XD; Bai JY; Guo H; Yang SM
    Int Immunopharmacol; 2013 Aug; 16(4):444-50. PubMed ID: 23714071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer.
    Amarnath SM; Dyer CE; Ramesh A; Iwuagwu O; Drew PJ; Greenman J
    Int J Oncol; 2004 Jul; 25(1):211-7. PubMed ID: 15202008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uses of telomerase peptides in anti-tumor immune therapy.
    Li H; Katik I; Liu JP
    Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
    Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
    Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine.
    Niu BL; Du HM; Shen HP; Lian ZR; Li JZ; Lai X; Wei SD; Zou LQ; Gong JP
    Vaccine; 2012 May; 30(23):3395-404. PubMed ID: 22480929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
    Dupont J; Latouche JB; Ma C; Sadelain M
    Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.
    Ayyoub M; Migliaccio M; Guillaume P; Liénard D; Cerottini JC; Romero P; Lévy F; Speiser DE; Valmori D
    Eur J Immunol; 2001 Sep; 31(9):2642-51. PubMed ID: 11536162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
    Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes.
    Tajima K; Ito Y; Demachi A; Nishida K; Akatsuka Y; Tsujimura K; Hida T; Morishima Y; Kuwano H; Mitsudomi T; Takahashi T; Kuzushima K
    Int J Cancer; 2004 Jun; 110(3):403-12. PubMed ID: 15095306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
    Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
    Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.